Health Condition 1: null- Tamaka Shwaasa (Bronchial Asthma)
Conditions
Interventions
Intervention1: Ashtaangaavaleha: Dose daily in two divided doses
2 to 4 years 3 grams, 5 to 7 years 6 grams,8 to 10 years 9 grams,11 to 13 years 12 grams, Above 13 years 15 grams,Duration of thera
Sponsors
The Director
The Director
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosed cases of Tamaka Shwasa Bronchial Asthma with at least 3 episodes of asthma symptoms during the previous year Severity as mild to moderate stable asthma defined by FEV 1 more than 60 persent and less than 80 persent of that predicted by Polgar equation Able to generate a peek inspiratory flow rate of 60 L per minute Patients on other drug therapy will be included only after completion of wash out period prescribed Parents legal guardians willing to give written informed consent
Exclusion criteria
Exclusion criteria: Evidence of active concomitants pulmonary disease other than asthma Evidence of requirement of intubations for asthma, or had been hospitalized for asthma within one month before Had unresolved sinus disease or an unresolved upper or lower respiratory tract infection within 3 weeks More than 4 short courses of oral corticosteroids within the year preceding the screening visit, or any oral corticosteroids in the preceding 4 weeks Use of Astemizole, Nedocromil, Cromolyn, long acting β agonists, Ketotifen, or Theophylline within 2 weeks before Concomitant severe decompensated systemic disease (cardiovascular, renal, hepatic, endocrine, hematological, neurological, immunological)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in signs and symptoms of Tamaka Shwasa vis a vis Bronchial Asthma, Improvement in pulmonary function tests parameters, Improvement in frequency and severity in daytime asthma symptoms, overnight asthma symptoms cough, wheezing, trouble breathing and activity limitation Timepoint: Both groups will be assessed before treatment period and after eight weeks of treatment period | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive changes in blood picture, Reduction in Eosinophils count in blood chemistry, Improvements in Ig E antibody levels in serum, The improvement in QOL (Quality of life Parameters) Timepoint: Both groups will be assessed before treatment period and after eight weeks of treatment period | — |
Countries
India
Contacts
Public ContactDr Kalpana S Patel
IPGT and RA Jamnagar Gujarat
Outcome results
None listed